<?xml version="1.0" encoding="UTF-8"?>
<references>
<reference>
  <a1>García-Sanz, R.</a1>
  <a2>Oriol, A.</a2>
  <a2>Moreno, M.J.</a2>
  <a2>Rubia, De La</a2>
  <a2>Payer, A.R.</a2>
  <a2>Hernández, M.T.</a2>
  <a2>Palomera, L.</a2>
  <a2>Teruel, A.I.</a2>
  <a2>Blanchard, M.J.</a2>
  <a2>Gironella, M.</a2>
  <a2>Ribas, P.</a2>
  <a2>Bargay, J.</a2>
  <a2>Abellá, E.</a2>
  <a2>Granell, M.</a2>
  <a2>Ocio, E.M.</a2>
  <a2>Ribera, J.M.</a2>
  <a2>San Miguel, J.F.</a2>
  <a2>Mateos, M.V.</a2>
  <t1>Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial</t1>
  <t2>Haematologica</t2>
  <sn/>
  <op/>
  <vo/>
  <ab/>
  <la>eng</la>
  <k1/>
  <pb/>
  <pp/>
  <yr>2015</yr>
  <ed/>
  <ul>http://zaguan.unizar.es/record/46922/files/texto_completo.pdf;
	http://zaguan.unizar.es/record/46922/files/texto_completo.jpg?subformat=icon;
	</ul>
  <no>Imported from Invenio.</no>
</reference>

</references>